ACS Journal Cancer recently shared on X:

“This new review article from Wei Ying Jen, Marina Konopleva, and Naveen Pemmaraju is all about Tagraxofusp for BPDCN. Learn how it is being used in combination to improve outcomes in BPDCN and AML, and its developing role in other hematological malignancies.”

Read further.
Source: ACS Journal Cancer/X

About OncoDaily

OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time, it became one of the leading oncology media platforms globally.

OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.

The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”